The team
behind Renova

Renova is built around an idea with a long track record. Kirk Hammond first showed in the late 1990s that restoring AC6 could strengthen the failing heart, and that work moved from mouse studies to large-animal models to a randomized, placebo-controlled trial published in JAMA Cardiology.
We are cardiologists, scientists, and drug developers who have run clinical trials, built manufacturing processes, and taken therapies through FDA review. We are focused on developing the science, following where it leads, and turning it into cardiovascular therapies with a lasting impact for patients.
Heart failure affects nearly 8 million American adults and is one of the most common reasons people are hospitalized.
Today's medicines ease the strain on the heart and have meaningfully improved survival, yet even on the best available therapy, substantial risk of hospitalization and death remains. None of these medicines directly targets the heart muscle's ability to contract.
To close that gap, we are developing gene therapies designed to work alongside the medicines patients already take. We are testing them the way any heart failure therapy should be tested: in randomized, placebo-controlled trials, reported in full.
Leadership
Alan Horsager, PhD
President & CEO
Alan built and led an academic gene therapy lab at USC before serving as CEO of two biotech companies, one exited via acquisition, and leads Renova's strategy, capital formation, and FDA re-engagement.
LinkedIn of Alan Horsager, PhD
Shawn Swaney, CPA
Chief Financial Officer
Shawn brings more than 30 years of financial and executive leadership across public and private high-growth companies, including more than $180 million raised and a successful acquisition.
LinkedIn of Shawn Swaney, CPA
Clinical & Regulatory
Rickey Reinhardt, MD, PhD
Clinical Development Strategy
Rickey brings 30 years of drug development experience focused on gene therapy and cardiovascular disease, including as Chief Medical Officer of XyloCor Therapeutics, and leads clinical trial design for RT-100.
LinkedIn of Rickey Reinhardt, MD, PhD
Marc Semigran, MD
Cardiology, Clinical and Regulatory Strategy
Marc led Massachusetts General Hospital's Heart Failure and Cardiac Transplant Program, served as CMO and SVP of MyoKardia through the mavacamten clinical development program, and advises Renova on endpoints and safety.
LinkedIn of Marc Semigran, MD
Julie Hagan, MS
Regulatory Affairs Lead, Strategy & Operations
Julie brings more than 20 years of global regulatory affairs experience across gene therapy (AAV, CRISPR), cell therapy, RNA/ASO/LNP, and orphan and rare disease programs, and leads Renova's IND and FDA efforts and interactions with Health Authorities.
LinkedIn of Julie Hagan, MS
CMC
Raj Poudel, PhD
CMC Strategy
Raj is Head of CMC at Mammoth Biosciences, with more than 15 years across cell and gene therapy, including CMC work behind Breyanzi and Abecma, and leads CMC strategy for RT-100.
LinkedIn of Raj Poudel, PhD
Stephen Kaminsky, PhD
CMC and Technology Transfer
Stephen is Associate Director of Weill Cornell's Belfer Gene Therapy Core Facility, which manufactured the clinical material for RT-100's original trial.
LinkedIn of Stephen Kaminsky, PhD
Scientific Advisory Board
H. Kirk Hammond, MD
Founder; Chair, Scientific Advisory Board; Consultant
Kirk originated AC6 and urocortin 2 gene transfer, the biology underlying RT-100 and RT-200, assisted by Dr. N. Chin Lai and Dr. Mei Hua Gao. He is Professor of Medicine Emeritus at UC San Diego and a former VA San Diego cardiologist.
Publications of H. Kirk Hammond, MD
Roger M. Mills, MD
Clinical Advisor, Scientific Advisory Board
Roger, a cardiologist and former University of Florida Professor of Medicine, served at Johnson & Johnson as VP of Medical Affairs at Scios Inc. and chair of Janssen's cardiovascular drug safety committee.
LinkedIn of Roger M. Mills, MD
Scott Flamm, MD, MBA
Medical Affairs Advisor, Scientific Advisory Board
Scott led cardiovascular imaging at the Cleveland Clinic for 17 years, is a past president of the Society for Cardiovascular Magnetic Resonance, and brings imaging and clinical trial expertise to RT-100's endpoints.
LinkedIn of Scott Flamm, MD, MBA









